Zivo Bioscience Reports Unregistered Equity Sale

TL;DR

Zivo sold warrants, dilution alert!

AI Summary

On January 22, 2025, Zivo Bioscience, Inc. reported an unregistered sale of equity securities. The company issued warrants to purchase shares of its common stock. Specific details regarding the number of warrants, the exercise price, and the total proceeds from this sale were not disclosed in this filing.

Why It Matters

This filing indicates Zivo Bioscience has issued new equity, which could dilute existing shareholders or provide capital for operations.

Risk Assessment

Risk Level: medium — Unregistered sales of equity can signal financial distress or a need for capital, potentially leading to dilution for existing shareholders.

Key Players & Entities

• Zivo Bioscience, Inc. (company) — Registrant
• January 22, 2025 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• Troy, Michigan (location) — Principal Executive Address

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ZIVO OTCQB Warrants to
• $0 — f the Company's common stock, par value $0.001, in transactions not involving a pu
• $20.19 — o one accredited investor at a price of $20.19 per share, resulting in gross proceeds
• $1.5 million — ss proceeds to the Company of just over $1.5 million. Further, an aggregate of 38,478 shares

Filing Documents

• zivo_8k.htm (8-K) — 25KB
• 0001654954-25-000805.txt ( ) — 158KB
• zivo-20250122.xsd (EX-101.SCH) — 6KB
• zivo-20250122_lab.xml (EX-101.LAB) — 15KB
• zivo-20250122_cal.xml (EX-101.CAL) — 1KB
• zivo-20250122_pre.xml (EX-101.PRE) — 11KB
• zivo-20250122_def.xml (EX-101.DEF) — 4KB
• zivo_8k_htm.xml (XML) — 5KB

02. Unregistered Sales of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities. Since the filing of our last Form 10-Q with the Securities and Exchange Commission (the "SEC") on November 14, 2024, until January 22, 2025, Zivo Bioscience, Inc. (the "Company") issued an aggregate of 191,698 shares of the Company's common stock, par value $0.001, in transactions not involving a public offering. Of the total shares issued, 75,000 shares were sold to one accredited investor at a price of $20.19 per share, resulting in gross proceeds to the Company of just over $1.5 million. Further, an aggregate of 38,478 shares were granted as restricted stock to non-employee members of the board of directors of the Company pursuant to the 2024 Equity Incentive Plan for Non-Employee Directors. Lastly, as previously disclosed in a Form 8-K filed with the SEC on January 15, 2025, the Company agreed to issue shares to certain investors in exchange for cancellation of certain License and Co-Development Participation Agreements and the related revenue-sharing arrangement with the investors (the "Exchange Program"). As of the date hereof, the Company has issued an aggregate of 78,320 shares to the investors under this Exchange Program. No general solicitation was made, and no underwriting discounts were given or paid in connection with this transaction. The shares of common stock issued in the foregoing transactions were not registered under the Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state, and were issued to "accredited investors" in reliance on an exemption from registration afforded by Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act and corresponding provisions of state securities laws, which exempts transactions by an issuer not involving any public offering. As of January 20, 2025, the Company has 3,738,033 shares of common stock outstanding. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZIVO BIOSCIENCE, INC. By: /s/ Keith Marchiando Keith Marchiando Chief Financial Officer Date: January 27, 2025 3

View Full Filing

View this 8-K filing on SEC EDGAR